HGF修饰的MSCs治疗股骨头坏死的基础研究

Treatment of femoral head osteonecrosis with hepatocyte growth factor-modified mesenchymal stem cells

  • 摘要: 目的 研究肝细胞生长因子(HGF)修饰的骨髓间充质干细胞(MSCs)治疗股骨头坏死(ONFH)的可行性。方法 以40只新西兰兔为实验动物制作股骨头坏死模型,2周后随机分为MSCs组及HGF/MSCs组,透视下行股骨头钻孔后分别注入MSCs悬液及HGF/MSCs悬液,4周后处死动物,对股骨近端进行Micro-CT、组织学及免疫组化观察,了解两种方法对股骨头坏死灶的治疗差异。结果 HGF/MSCs悬液的Micro-CT影像学指标显示骨小梁数量增加,钻孔隧道消失,BMD(517.41±69.37)mg/ml,TMD(817.61±12.31)mg/ml,BVF0.61±0.11,主要指标均优于MSCs悬液组,组织学及免疫组化结果方面也有明显改善。结论 HGF/MSCs悬液可有效治疗股骨头坏死。

     

    Abstract: Objective To study whether osteonecrosis of femoral head can be treated with hepatocyte growth factor(hHGF)-modified mesenchymal stem cells(MSC). Methods A model of femoral head osteonecrosis was established using 40 New Zealand rabbits.The animals were randomly divided into MSC group and HGF/MSC group.Four weeks after the suspension of MSC and HGF/MSC was injected into the drilled holes of femoral head,the rabbits were sacrificed.The histology and immunohistochemistry of the proximal femoral head were observed by Micro-CT for the difference in efficiency of the two treatment modalities on osteonecrosis of femoral head. Results Micro-CT showed that the number of bone trabeculas was greater in HGF/MSC group than in MSC group.The drilled holes of femoral head were disappeared.The BMD(517.41±69.37)mg/ml,TMD(817.61±12.31)mg/ml and BVF(0.61±0.11) were higher in HGF/MSC group than in MSC group.The histology and immunochemistry were also more significantly improved in HGF/MSC group than in MSC group. Conclusion Osteonecrosis of femoral head can be effectively treated with HGF/MSC suspension.

     

/

返回文章
返回